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A B S T R A C T
Background: Generalised high bone mass (HBM), associated with features of a mild skeletal dysplasia, has a
prevalence of 0.18% in a UK DXA-scanned adult population. We hypothesized that the genetic component of
extreme HBM includes contributions from common variants of small eﬀect and rarer variants of large eﬀect, both
enriched in an extreme phenotype cohort.
Methods: We performed a genome-wide association study (GWAS) of adults with either extreme high or low
BMD. Adults included individuals with unexplained extreme HBM (n=240) from the UK with BMD Z-scores
≥+3.2, high BMD females from the Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) (n= 1055)
with Z-scores +1.5 to +4.0 and low BMD females also part of AOGC (n=900), with Z-scores −1.5 to −4.0.
Following imputation, we tested association between 6,379,332 SNPs and total hip and lumbar spine BMD Z-
scores. For potential target genes, we assessed expression in human osteoblasts and murine osteocytes.
Results: We observed signiﬁcant enrichment for associations with established BMD-associated loci, particularly
those known to regulate endochondral ossiﬁcation and Wnt signalling, suggesting that part of the genetic
contribution to unexplained HBM is polygenic. Further, we identiﬁed associations exceeding genome-wide
signiﬁcance between BMD and four loci: two established BMD-associated loci (5q14.3 containing MEF2C and
1p36.12 containing WNT4) and two novel loci: 5p13.3 containing NPR3 (rs9292469; minor allele frequency
[MAF]= 0.33%) associated with lumbar spine BMD and 11p15.2 containing SPON1 (rs2697825; MAF=0.17%)
associated with total hip BMD. Mouse models with mutations in either Npr3 or Spon1 have been reported, both
have altered skeletal phenotypes, providing in vivo validation that these genes are physiologically important in
bone. NRP3 regulates endochondral ossiﬁcation and skeletal growth, whilst SPON1 modulates TGF-β regulated
BMP-driven osteoblast diﬀerentiation. Rs9292469 (downstream of NPR3) also showed some evidence for as-
sociation with forearm BMD in the independent GEFOS sample (n=32,965). We found Spon1 was highly ex-
pressed in murine osteocytes from the tibiae, femora, humeri and calvaria, whereas Npr3 expression was more
variable.
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Conclusion: We report the most extreme-truncate GWAS of BMD performed to date. Our ﬁndings, suggest po-
tentially new anabolic bone regulatory pathways that warrant further study.
1. Introduction
Osteoporotic fractures are a major cause of morbidity and mortality,
with associated healthcare costs exceeding $20 billion in the United
States [1]. Understanding genetic regulation of bone signalling path-
ways, which underlie the pathogenesis of skeletal disease, aids devel-
opment of novel therapeutics to increase bone mass [2]. Genome-wide
association studies (GWAS) of bone density phenotypes, drawn mainly
from general populations, have identiﬁed multiple BMD-associated loci,
although together these only explain a relatively small proportion
(5.8–11.8%) of variance in bone phenotypes [3, 4]. An alternative ap-
proach is to focus on rare individuals who represent extremes of a
quantitative phenotype, i.e. BMD, to identify variants of relatively large
eﬀect. At the very extremes, high bone mass (HBM) and low bone mass
(LBM) occur due to monogenic mutations (e.g. in SOST, LRP5 or LRP4
in HBM, and COL1A1, COL1A2, LRP5 and others in LBM); however,
such monogenic disorders fail to explain the vast majority of in-
dividuals with either HBM or LBM [5]. Conceivably, extreme HBM or
LBM may both constitute polygenic conditions, either explained by
variants in the same genes that determine BMD in the general popu-
lation [3], or in novel extreme bone mass genes. In support of this, a
previous GWAS of a moderate high and low BMD population replicated
associations in 21 loci previously established to be BMD-associated
from analyses of normal populations and identiﬁed six new genetic
associations, highlighting the eﬃciency of extreme-truncated selection
for quantitative trait GWAS design [6]. Such augmentation of statistical
power through analysis of extreme phenotypes has been advantageous
in a range of clinical phenotypes [7–10] and is an established approach
to investigate complex disease [11, 12].
Unexplained generalised HBM has a prevalence of 0.18% amongst a
UK DXA-scanned adult population; aﬀected individuals also have fea-
tures suggestive of a mild skeletal dysplasia, such as mandibular en-
largement and enthesophytes [13, 14]. We hypothesized that un-
explained extreme HBM is genetically determined by variation in both
established and novel BMD loci. In this GWAS of individuals with un-
explained extreme HBM, we aimed to ﬁrst determine whether variants
in known loci account for BMD variation in this population. Secondly,
we aimed to identify novel loci and validate the use of extreme BMD
populations for genetic discovery. We augmented our unexplained ex-
treme HBM population with a further moderate high BMD population
and made comparison with an extreme-low BMD population to enhance
statistical power. We investigated associated gene expression using
human osteoblast expression quantitative trait loci (eQTL) and novel
murine osteocyte expression data.
2. Methods
We investigated three populations to identify genetic determinants
of unexplained high BMD (Fig. 1, Supplementary Table 1). Individuals
included: [1] UK-based unexplained extreme HBM index cases
(n= 240) with total hip (TH) or ﬁrst lumbar vertebra (L1) Z-score
≥+3.2; [2] more moderate high BMD females from the Anglo-Aus-
tralasian Osteoporosis Genetics Consortium (AOGC) (n=1055) with
TH Z-scores between +1.5 and +4.0 [3] low BMD females also part of
AOGC (n=900), with TH Z-scores between −1.5 and −4.0, re-
presenting an extreme-low ‘super-control’ group, enhancing statistical
power. Australian individuals who self-identify as Caucasian have been
shown to be representative of UK populations regarding population
stratiﬁcation [6].
2.1.1. High bone mass cases (Supplementary methods)
The HBM study is a UK based multi-centred observational study of
adults with unexplained HBM, identiﬁed incidentally on routine clinical
DXA scanning. Full details of DXA database screening and participant
recruitment have previously been reported [13]. In brief, DXA data-
bases containing 335,115 DXA scans were initially searched for a BMD
T or Z-score≥+4 at any site within the lumbar spine (LS) or hip, at UK
13 centres. All 1505 DXA images were visually inspected; 962 cases
with established and/or artefactual causes of raised BMD were ex-
cluded, taking particular care to exclude osteoarthritic artefacts af-
fecting the lumbar spine (see Supplementary Methods 1). A generalised
HBM trait would be expected to aﬀect both spine and hip BMD, though
Fig. 1. Flow diagram explaining recruitment of study populations with BMD data availability enabling lumbar spine (LS) and total hip (TH) GWAS (Stage 1). BMD;
Bone Mineral Density. AOGC; Anglo-Australasian Osteoporosis Genetics Consortium. QC; Quality Control steps including exclusion of ethnic outliers.
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not necessarily to the same extent. Hence, we reﬁned the deﬁnition of
HBM index cases as a) L1 Z-score of≥+3.2 plus TH Z-score of≥+1.2
and/or b) TH Z-score≥+3.2 plus L1 Z-score of≥+1.2 (using age and
gender-adjusted BMD Z-scores). A threshold of +3.2 was in keeping
with the only published precedent for identifying HBM previously de-
scribed using DXA [15], and these threshold combinations most ap-
propriately diﬀerentiated generalised HBM from artefact. Z rather than
T-score was used to limit age bias. Of 533 unexplained HBM index cases
invited to participate, 248 (47%) were recruited between 2008 and
2010 [13], aged 18–90 years. After Sanger sequencing all HBM index
cases, we excluded seven with LRP5 mutations and one who carried a
SOST mutation [5], leaving 240 unexplained HBM individuals for
GWAS.
This study was approved by the Bath Multi-centre Research Ethics
Committee (REC: 05/Q2001/78) and at each NHS Local REC.
2.1.2. Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) high
BMD cases and low BMD controls (Supplementary methods)
The AOGC population included 1128 Australian, 74 New Zealand
and 753 British women, aged between 55 and 85 years, ﬁve or more
years postmenopausal, with either moderate high BMD (age and
gender-adjusted BMD Z-scores of +1.5 to +4.0, n=1055) or low BMD
(age- and gender-adjusted BMD Z-scores of−4.0 to−1.5, n= 900) [6]
(Fig. 1). Low BMD controls were excluded if they had secondary causes
of osteoporosis (as previously described [6]).
The AOGC study was approved by the Queensland Oﬃce of Human
Research Ethics Committee (Ref: 2008/018), the University of
Queensland (Ref: 200800376) and/or relevant research ethics autho-
rities at each participating centre. Some participants were recruited
through genetic and/or clinical studies (all with appropriate ethical
approval) but also provided written informed consent to contribute to
collaborative genetic studies [16–18].
2.2. Genotyping and quality control
SNP genotyping was performed using Inﬁnium OmniExpress-12v1.0
for the UK unexplained HBM cases (n= 240); and Illumina Inﬁnium II
HumHap300 (n=140), 370CNVDuo (n=4), 370CNVQuad
(n=1882) and 610Quad (n= 10) chips for the AOGC high and low
BMD individuals (n= 2036), at the University of Queensland
Diamantina Institute, Brisbane, Australia. For each study population
genotype clustering was performed using Illumina's BeadStudio soft-
ware; all SNPs with quality scores< 0.15 and all individuals with<
98% genotyping successes were excluded. Cluster plots from the 500
most strongly associated loci were manually inspected and poorly
clustering SNPs excluded from analysis. Using PLINK, an IBS/IBD
analysis was used to detect and exclude samples with cryptic related-
ness [19]. SNPs with minor allele frequency (MAF)< 1%, those with
excess missingness (> 95%) and those not in Hardy-Weinberg equili-
brium (p < 1×10–6) were removed, leaving 181,323 SNPs in total
shared across all chip types.
2.3. Population stratiﬁcation
We used EIGENSTRAT software to detect population stratiﬁcation,
excluding 24 regions of long range linkage disequilibrium (LD) in-
cluding the MHC, before running a principal component analysis using
merged genotype data [20]. Eight unexplained HBM cases were re-
moved as ethnic outliers (Fig. 1). Four eigenvectors, principal compo-
nents of a genetic covariance matrix, were used as covariates to adjust
for population stratiﬁcation in all GWAS models.
2.4. Imputation
Imputation analyses were conducted for all datasets separately.
Phasing was carried out using SHAPEIT [21] and imputation with
IMPUTE2 [22], using a merged 1000G/UK10K reference dataset as the
reference set of haplotypes, enabling imputation down to MAF 0.01.
SNPs with high imputation quality (‘info score’ > 0.8) were included
[23]; this stringent threshold was used as the two populations were
imputed separately. All SNPs were ﬁltered for missing data< 0.05,
HWE 1×10−6 and MAF > 0.01 (thus excluding rare HBM-causing
monogenic disease). Additional concordance ﬁltering was performed,
excluding genotyped SNPs with r2 < 0.9 between original and masked
IMPUTE2 imputed genotype, and those imputed SNPs in linkage dis-
equilibrium (LD) (r2 > 0.2) with these excluded SNPs [24]. We further
excluded known problematic UK10K imputed SNPs [25], and SNPs not
present in both the 1000G and UK10K cohort imputation panels.
2.5. Stage 1: genome-wide association analysis
Association analyses for imputed genotypes were assessed with
probabilistic genotypes under an additive (per allele) linear genetic
model. Following imputation, 6,379,332 SNPs were tested for associa-
tion in two quantitative trait analyses using the software SNPTEST.
Quantitative analyses used genotyping data from individuals with UK
unexplained HBM (n=232), AOGC high BMD (n=1026) and AOGC
low BMD (n=852) (Fig. 1), and tested association between SNPs and
(i) TH-BMD Z-score (combined n= 2110) and (ii) LS-BMD Z-score
(combined n= 1380). To explore whether genetic associations were
speciﬁc to the very extremes of the BMD distribution, two additional
quantitative analyses also tested these same associations restricted to
the UK HBM cases (n=232) and AOGC low BMD (n=852) individuals
again for (i) TH-BMD Z-score (n=1084) and (ii) LS-BMD Z-score
(n= 767). Quantitative models were adjusted for a priori covariates
age, age2, study centre, and four eigenvectors. BMD Z-score was used as
it standardises BMD by gender. Because gender was not evenly dis-
tributed within study populations (only 44 male individuals, all
amongst unexplained HBM cases), inclusion as a covariate risks in-
troducing sparse data bias [26], hence gender was not used as a cov-
ariate. The genomic inﬂation factors (λ) were 1.016 and 0.9973 for TH-
BMD and LS-BMD respectively, and 1.037 and 1.016 in the restricted
analyses (Supplementary Fig. 1). All LocusZoom association plots in-
cluded both genotyped and imputed SNPs [27]. In pre-planned sensi-
tivity analyses, all quantitative models were re-run with additional
adjustment for height. Weight was not included as a covariate as in-
creased android fat mass constitutes part of the unexplained HBM
phenotype [28].
To establish whether BMD-increasing alleles were enriched in un-
explained HBM, we performed a case-control GWAS of HBM cases
versus unselected control individuals from the well described second
Wellcome Trust Case Control Consortium (WTCCC2) (n=5667) re-
presenting the general population, in whom BMD whilst unmeasured, is
considered to be normal [29].
2.6. Stage 2: replication in GEFOS
We used publicly available data from the GEFOS 2015 meta-analysis
(n= 32,965) of whole-genome sequencing, whole-exome sequencing,
and deep imputation of genotype data (www.gefos.org/?q=content/
data-release-2015) for SNPs associated with femoral neck (FN), LS and
forearm BMD (chieﬂy distal radius measured), which had been adjusted
for age, age2, gender and weight [30]. As the AOGC cohort had con-
tributed to the GEFOS meta-data, the GEFOS 2015 meta-analysis was
rerun excluding AOGC data (n=30,970), with results used to assess
replication of SNPs surpassing GWA signiﬁcance (p < 5×10−8) in
Stage 1.
2.7. Stage 3: gene expression
2.7.1. Gene expression in primary human osteoblasts
To assess whether identiﬁed variants were involved in the
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regulation of messenger RNA levels via eQTLs, we performed cis-eQTL
analyses of SNPs surpassing the GWA threshold (p < 5×10−8) in 95
primary human osteoblasts (as described previously [31]; GEO re-
ference GSE15678), using genome-wide SNP data imputed to the
combined UK10K and 1000G Phase 1 v3 reference panel [23]. Using
α=0.05 with Bonferroni correction, we aimed to identify gene targets
for novel SNPs identiﬁed in Stage 1 (n= 4) and SNPs in LD (n=31;
r2 > 0.8), by examining gene expression proﬁles of all genes within
1Mb of each lead SNP (included 24 gene probes).
2.7.2. Gene expression in murine osteocytes
Osteocyte expression was determined through an analysis of whole
transcriptome sequencing data from the primary osteocytes of four
diﬀerent bone types (tibia, femur, humerus and calvaria) from mice
(marrow removed, 16 week old female mice, strain C57BL6/NTac,
n=8 per bone) [32]. RNA-sequencing reads were trimmed of low
quality data using trimgalore [33], aligned to the GRCm38.p3 genome
guided by the GENCODE M5 transcriptome annotation [34] using STAR
[35] and expression quantiﬁed using RSEM [36]. A threshold of gene
expression was determined based on the distribution of FPKM-nor-
malised (Fragments Per Kilobase per Million mapped reads) gene ex-
pression for each sample [37]. “Expressed” genes were above this
threshold for all 8 of 8 replicates in any bone type. Osteocyte enriched
expression of these genes in the skeleton was determined by comparing
transcriptome-sequencing data from bone-samples with osteocytes
isolated versus those samples with marrow left intact (10-week old
male mice, strain C57BL6/NTac, n=5 per group) [32].
3. Results
3.1. Stage 1: analyses concerning established BMD-associated loci
In total, 49 of 64 SNPs previously associated at GWAS signiﬁcance
level with DXA BMD and/or fracture by Estrada et al. [3] were available
in our imputed dataset (15 were not as they were either not imputed
(n=6), on chromosome X (n=1), or were excluded by ﬁltering for
concordance (n=7) or infoscore (n= 1)). The previously identiﬁed
lead SNP at the MEF2C locus was associated with TH BMD at genome-
wide signiﬁcance (p < 5×10−10), and lead SNPs at WNT4/ZBTB40,
SOX6 and CTNNB1 loci were strongly suggestive of association
(p < 1×10−6). Overall, 29 of the available SNPs (59%) were asso-
ciated with BMD at p < 0.05 (Supplementary Table 2). QQ plots of p
values for the 49 tested SNPs assessing association at either TH or LS
BMD (Supplementary Fig. 2) showed enrichment for known BMD-as-
sociated loci (i.e. observed p values were much smaller than those ex-
pected). However, to determine whether this enrichment is explained
by excess variation in common BMD-increasing alleles and/or BMD-
decreasing alleles, we ran two case-control GWAS' (Fig. 2). The ﬁrst
compared unexplained HBM cases against AOGC low BMD controls
conﬁrming the enrichment seen in quantitative GWAS. The second
compared unexplained HBM cases against WTCCC2 controls considered
to have normal BMD, conﬁrming that unexplained HBM is polygenic
reﬂecting enrichment at known common BMD-associated loci (Fig. 2).
As expected, βs for BMD measured at both the TH and LS were
substantially larger in this HBM GWAS compared to the published
general population GWAS from GEFOS [3]; all directions of eﬀect were
consistent (Supplementary Table 2), including when analysis was re-run
including additional co-variates of gender and weight (Supplementary
Table 3).
3.2. Stage 1: GWAS discovery ﬁndings
Our quantitative trait analyses identiﬁed SNPs at four loci that
surpassed a genome-wide signiﬁcant threshold (p < 5×10−8)
(Table 1, Supplementary Fig. 3). Two loci, near NPR3 and within
SPON1, have not been implicated in GWAS of BMD previously, whereas
MEF2C and WNT4/ZBTB40 loci represent established BMD-associated
regions [3] (Supplementary Fig. 4a & b). MEF2C and WNT4/ZBTB40
loci were most strongly associated with TH-BMD Z-score, as was SPON1
in analyses restricted to unexplained HBM and AOGC low-BMD in-
dividuals, suggesting this association may be speciﬁc to extreme BMD
(rs2697825 lies within intron 3 of SPON1, Fig. 3). The NPR3 locus was
most strongly associated with LS-BMD Z-score (rs9292469 is 48.5 kb 3′
of NPR3 with the LD block including part of this gene) (Fig. 4). As a SNP
in the NPR3 locus has previously been associated with adult height and
truncal length [38], we re-ran our GWAS model with additional height
adjustment; however, this did not attenuate our identiﬁed association
(β 0.23, p= 2.25× 10−8) (Supplementary Table 4, Supplementary
Fig. 5). Height adjustment did however partially attenuate the asso-
ciation between rs2697825 (within the SPON1 locus) and TH-BMD Z-
Fig. 2. QQ plot for p values for 49 established BMD-
associated loci in Case-Control GWAS of (A) un-
explained HBM cases vs. AOGC low BMD controls,
and (B) unexplained HBM cases vs. the second
WTCCC2 (Wellcome Trust Case Control Consortium)
controls. In both plots, the strength of observed as-
sociations for many SNPs far exceeded expected va-
lues.
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score (Supplementary Table 4). We further identiﬁed 75 loci suggestive
for association (p < 5×10−5) with TH-BMD and 71 with LS-BMD
(Supplementary Tables 5 & 6). Results were unchanged in a sensitivity
analysis excluding the 48 men (data not shown).
3.3. Stage 2: replication
The four SNPs identiﬁed in Stage 1 were assessed for replication
using the GEFOS 2015 meta-analysis adjusted for age, age2, gender and
weight, excluding AOGC data (Table 2). The MEF2C locus (rs1366594)
replicated strongly in association with FN BMD, and to a lesser extent
forearm BMD, but not with LS-BMD. The WNT4/ZBTB40 locus
(rs113784679) also replicated in association with FN BMD, and to a
lesser extent LS-BMD. For both these loci the direction of association
was concordant in the discovery and replication sets. The NPR3 locus
(rs9292469) showed no association with LS-BMD, but, although not
withstanding correction for testing 4 SNPs, was weakly associated with
BMD measured at the forearm (p= 0.0198) and FN (p=0.06), the
direction of association being concordant with the discovery set. The
SPON1 locus (rs2697825) was associated weakly (not withstanding
multiple testing correction) with BMD measured at the forearm
(p=0.029); however, the direction of eﬀect was discordant, and no
association was seen at the LS or FN. Unfortunately, non-weight ad-
justed GEFOS GWAS meta-data were not available for replication.
3.4. Stage 3: gene expression
3.4.1. Gene expression in primary human osteoblasts
We tested the association of potential functional SNPs with cis-eQTL
expression of genes in human osteoblasts from 95 donors [31] in whom
genotype data were available and imputed to a combined UK10K/
1000G reference panel [23]. We identiﬁed potential target genes based
on cis-eQTL evidence in human osteoblasts for two of four of our lead
SNPs (Supplementary Table 7). Whilst rs113784679 was identiﬁed as
having a potential target gene of WNT4 (p= 0.002), rs1366594
(MEF2C nearest gene) had no evidence of a target gene in osteoblasts.
eQTL data did not support a speciﬁc gene association for rs9292469
(NPR3 nearest gene) (osteoclast and chondrocyte expression data were
not available). SNPs in LD with rs2697825, which lies within an intron
(3/16) of SPON1, were associated with BTBD10 expression after Bon-
ferroni correction (Supplementary Tables 8 & 9). BTBD10 has not pre-
viously been associated with bone regulation. We assessed all SNPs
lying 500 kb either side of BTBD10 in GEFOS 2015 meta-analysis
summary data; using ANNOVAR for SNP annotation 66,654 SNPs were
assessed for association with BMD (at FN, LS and forearm) [39], but no
evidence of association was detected (all p > 5×10−4).
3.4.2. Expression of Spon1 and Npr3 in murine osteocytes
Spon1 and Npr3 were investigated as the two genes lying closest to
Table 1
Stage 1 - genome-wide signiﬁcant SNPs with p < 5×10−8 associated with BMD Z-score measured at the total hip and lumbar spine.
rsID Locus Position Closest gene/candidate EA EAF Total hip BMD Z-score Lumbar spine BMD Z-score
n β SE p n β SE p
rs1366594 5q14.3 88376061 MEF2C C 0.47 2110 −0.191 0.031 4.83×10−10 1380 −0.103 0.039 7.85× 10−3
rs113784679 1p36.12 22648479 WNT4/ZBTB40 T 0.04 2110 0.511 0.088 8.40×10−9 1380 0.215 0.115 6.19× 10−2
rs9292469 5p13.3 32840210 NPR3 T 0.33 2110 0.108 0.033 1.00× 10−3 1380 0.232 0.041 2.70×10−8
rs2697825 11p15.2 14089431 SPON1 G 0.17 1084a 0.310 0.056 4.93×10−8 767a 0.188 0.065 3.92× 10−3
Chromosome position using: GRCh37.p13.
Quantitative analysis results shown use data from HBM, AOGC high BMD and AOGC low BMD cohorts, except awhich reﬂects analyses restricted to HBM and AOGC
low BMD cohorts. Model is adjusted for age, age2, centre and 4 PCs.
p < 5×10−8 appears in bold.
EA: Eﬀect Allele (BMD increasing); EAF: Eﬀect Allele Frequency. SE: Standard Error. β: eﬀect estimate – represents change in BMD Z-score per copy of the SNP EA.
Fig. 3. SPON1 regional association plot of the unexplained HBM cases and AOGC Low BMD controls in a quantitative trait GWAS of total hip BMD Z-Score, adjusted
for age, age2 and centre (1000 kb either side of rs2697825 shown). Square symbols indicate imputed SNPs; circles indicate those genotyped.
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SNPs identiﬁed in Stage 1. Spon1 was highly expressed in osteocytes in
all four bone types forming part of a characteristic “osteocyte sig-
nature”, which is a list of genes signiﬁcantly enriched in osteocytes
relative to other cells in the marrow space and actively expressed in
every replicate (Table 3). Npr3 was expressed in osteocytes although at
much lower levels than Spon1 and despite some variability it was ac-
tively expressed in all tibia and 7 of 8 humeri samples. Considering the
osteoblast eQTL results, we also examined Btbd10 expression. Btbd10
was expressed in whole femur, tibia, humerus and skull but its ex-
pression was not enriched in osteocytes.
4. Discussion
Firstly, we have identiﬁed over-representation of signal from known
BMD loci, implying that unexplained HBM is, at least in part, polygenic
in origin, inﬂuenced by common genetic variation. Secondly, our GWAS
has identiﬁed two genome-wide signiﬁcant SNPs, rs9292469 (3′ of
NPR3) and rs2697825 (within an intron of SPON1), and conﬁrmed two
established BMD-associated loci, MEF2C and WNT4/ZBTB40, despite
our limited sample size. Replication of rs9292469 was only weak
(concordant at distal forearm, rather than LS) and for rs2697825 was
discordant for both site (distal forearm, rather than hip) and direction.
However, two genes at these loci are expressed in bone, and mutations
of these genes in mice have been shown to inﬂuence bone mineral
content (BMC) (see below), giving support to these as novel HBM-as-
sociated genes, although further investigation is warranted.
4.1. Established BMD-associated loci
Of the four BMD-associated loci published by Estrada et al. and
identiﬁed in our analysis with p < 5×10−5, both MEF2C (for which
we found the strongest evidence of association) and SOX6 regulate
endochondral ossiﬁcation, linking this pathway to high BMD. MEF2C
controls chondrocyte hypertrophy, cartilage ossiﬁcation, and long-
itudinal bone growth in mice [40]. In addition to its role in bone mass
accrual during skeletal growth, endochondral ossiﬁcation is involved in
the formation of osteophytes and enthesophytes [41–43], both pre-
valent in unexplained HBM [14]. This raises the possibility that varia-
tion in endochondral ossiﬁcation pathway genes may be particularly
relevant in HBM, contributing pleiotropically to both higher BMD and
the wider associated skeletal phenotype. Besides WNT4, several SNPs
annotated to Wnt/β-catenin signalling pathway genes (MEF2C,
CTNNB1, RSPO3, and WLS), suggesting enhanced osteoblast activity
may also contribute to the HBM phenotype.
4.2. NPR3 (natriuretic peptide receptor 3)
The transmembrane protein NPR3 acts as a clearance receptor
modulating C-type natriuretic peptide (CNP) activity [37, 38]. The
importance of natriuretic peptide (NP) signalling in bone is increasingly
recognised. Natriuretic peptides ANP, BNP and CNP bind to three NP
receptors (NPRs): ANP and BNP preferentially bind to NPR1; NPR2 to
CNP; and NPR3 to all three NPs with similar aﬃnity. Additionally,
osteocrin, a protein secreted by osteoblast-lineage cells with homology
to NPs, also binds to NPR3 and can displace CNP, with subsequent
enhanced signalling through NPR2 [44]. NPR2 and NPR3 are both
expressed in chondrocytes and osteoblasts [28, 37]. Disrupted NP sig-
nalling results in marked skeletal phenotypes, with evidence from both
mouse and human data.
In humans, enhanced signalling results from autosomal dominant
activating NPR2 mutations causing bony overgrowth and tall stature
[41] (MIM# 615923). CNP overproduction causes bony overgrowth
and childhood skeletal abnormalities, particularly aﬀecting stature,
vertebrae and digital length [33–36] (MIM# 600296). Mice over-
expressing BNP or CNP have elongated bones [45, 46], as do those
overexpressing osteocrin, where NPR3 clearance of CNP is reduced,
resulting in increased NPR2 signalling [44]. Multiple spontaneous and
ENU (N-ethyl-N-nitroso urea) mouse strains with Npr3 mutations have
skeletal phenotypes with increased linear growth, bone area and ky-
phosis, as endochondral ossiﬁcation is delayed expanding the growth
plate [47–50]. BMC is increased in female, but not male homozygous
ENU mice, but as bone size is also increased, BMD is normal [48]. A
single histological section, which requires further validation, has sug-
gested trabeculae may be thicker and longer [49]. This skeletal over-
growth due to impaired endochondral ossiﬁcation is thought to result
from increased activation of p38 MAPK signalling [47–49], which
presumably delays growth plate quiescence.
In contrast, in humans attenuated NP signalling from loss-of-
Fig. 4. NPR3 regional association plot of the unexplained HBM, AOGC High BMD cases and AOGC Low BMD controls in a quantitative trait GWAS of lumbar spine
BMD Z-Score, adjusted for age, age2 and centre (1000 kb either side of rs9292469 shown). Square symbols indicate imputed SNPs; circles indicate those genotyped.
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function NRP2 mutations cause autosomal recessive acromesomelic
dysplasia with extreme short stature [39] (MIM# 602875); hetero-
zygous carriers display reduced height [40] (MIM# 616255). Whilst in
mice lacking CNP or with loss-of-function Npr2 mutations exhibit im-
paired longitudinal bone growth [51, 52].
In healthy adolescent humans, cross-sectional studies associate CNP
synthesis with pubertal linear growth in, supporting its role in en-
dochondral ossiﬁcation [53]. CNP is a weak natriuretic [54]; the role of
CNP/NRP3 regulation in explaining the hyponatraemia-low bone mass
association [55] is unknown. A GWAS identiﬁed association between an
NPR3 SNP (rs10472828) and adult height and truncal length [38];
importantly additional height-adjusted GWAS did not alter our ﬁnd-
ings. Of note, rs9292469 was associated with heel Broadband Ultra-
sound Attenuation (BUA) in the discovery phase of a GWAS of 14,258
participants (p= 3.1× 10−6); this ﬁnding was not replicated by meta-
analysis [56].
NPR3may be the target gene regulated by rs9292469, as our human
osteoblast eQTL data do not support an alternative target, and we and
others have shown Npr3 expression in the mouse skeleton [48]. Pre-
vious ﬁndings in our unexplained HBM population have shown that
although adult height is no diﬀerent from controls, trabeculae are
thicker increasing trabecular density [57, 58], possibly recapitulating
observations in Npr3-mutant mice [47, 49]. Our previous analyses
suggested unexplained HBM protects against age-associated declines in
trabecular BMD [57]. It is interesting that association was seen at the
lumbar spine, and weakly replicated at the distal forearm (although not
the LS); both are ‘trabecular-rich’ sites. Taken together, our ﬁndings are
consistent with previous observations of the role of NPR3 in regulating
skeletal growth.
4.3. SPON1 (Spondin 1/F-spondin)
rs2697825 is an intronic variant in SPON1. SPON1, coding for an
extracellular matrix glycoprotein, has not previously been associated
with a bone phenotype in humans. Spon1 knockout mice have a skeletal
phenotype consistent with HBM, with Spon1−/− mice at 6months age
having 60% higher bone volume, bone volume/total volume, cortical
area and trabecular number with reduced trabecular spacing [59]. In-
creased trabecular density and reduced endosteal expansion is seen in
human HBM [57, 58]. Serum CTX-1 and TRAP levels are normal in
Spon1−/− mice; however, TGF-β1 levels are reduced compared with
WT mice, whilst SMAD 1/5 activation is enhanced in both osteoblasts
and chondrocytes [59]. Although vertebrae and intramembranous
bones have not been characterized in Spon1−/− mice, overall ﬁndings
suggest reduced F-spondin activity decreases TGF-β1 levels, permitting
activation of SMAD family transcription factors which, in conjunction
with RUNX-2, promote BMP-driven osteoblast diﬀerentiation and hence
bone formation [60]. In addition to our observed osteocyte expression,
SPON1 expression is evident in several musculoskeletal tissues: the
embryonic growth plate cartilage, periodontal tissue and human and
rodent osteoarthritic cartilage where SPON1 expression appears to ac-
tivate TGF-β, inducing cartilage degradation [61–63]. Surprisingly, our
eQTL results suggested BTBD10 rather than SPON1 may be the target
gene for rs2697825. BTBD10 (Broad-Complex Tramtrack Domain
Containing 10) activates AKT by phosphorylation in neuronal and
pancreatic beta cells. BTBD10 overexpression accelerates growth of
pancreatic beta cells [64]. Despite expression in bone, BTBD10 has no
known role in bone regulation.
The relatively high frequency of the four identiﬁed SNPs (MAFs
0.04–0.47), compared to the rarity of the HBM phenotype, raises the
possibility that these common variants are in LD with rare high-eﬀect
variants. Some candidate studies in type 1 diabetes and Alzheimer's
disease identiﬁed stronger eﬀects from rare variants than the common
variants responsible for the initial identiﬁcation of the associated gene
(s) [65, 66]. However, this is not a universal ﬁnding; we note the re-
lative paucity of low frequency high-eﬀect variants in a recent fractures
analysis in 508,253 individuals [30]. No associations of rare variants in
NPR3 and SPON1 with BMD have been reported to date. Segregation
studies show the majority of BMD heritability is polygenic [67–71]. In
speciﬁc populations, monogenic eﬀects may be observed, but always on
a polygenic background [68, 71–73]. The extent to which variation
associated with NPR3 and SPON1 interacts with the enriched back-
ground polygenic architecture in HBM is unclear; we lacked power to
assess gene-gene interactions. However, our ability to detect association
with NPR3 and SPON1 loci, despite our relatively small sample size, is
testament to their likely eﬀect sizes in this unusual population.
GWAS of the AOGC cohort alone has been published previously [6];
however, associations with NPR3 and SPON1 loci were not identiﬁed.
Only 59% of the AOGC have LS BMD available, so adding 232 more
extreme HBM cases, in whom artefactual elevations in BMD were ex-
cluded, substantially increased statistical power. Moreover, the SPON1
locus was identiﬁed in analyses restricted to 232 unexplained HBM
(+AOGC low-BMD) individuals, who arguably represent a more pre-
cisely deﬁned and extreme population.
4.4. Limitations
The failure to replicate the associations of these genes at either LS or
FN in the GEFOS (minus AOGC) cohort suggests that either there are
diﬀerences in the genetic structure determining BMD in the extreme
discovery cohort compared with the general population; alternately,
these ﬁndings are false positives or the failure to replicate is a false
negative, due to statistical power issues or diﬀerences in covariate
handling. That the SPON1 locus was identiﬁed in analyses restricted to
a more precisely deﬁned and extreme population supports variation at
this locus being more speciﬁc to HBM individuals; however, this was
not the case for the NPR3 locus. Given the large size of the GEFOS
cohort, failure to replicate even at nominal levels of signiﬁcance, in-
dicates that at the very least these variants do not have the same eﬀect
size in the general population as observed here. Distinguishing between
these explanations requires further studies in extreme bone mass co-
horts, in much larger BMD association databases, or in genetically
modiﬁed animals. Unfortunately, no second extreme BMD population
currently exists, hence our use of a large general population dataset of
DXA-measured BMD. It was not possible to re-run a non-weight ad-
justed GWAS for BMD across all GEFOS cohorts for meta-analysis.
Comparisons between our study and those reported in the general po-
pulation are hindered by these diﬀerences; we were reluctant to adjust
for weight as this a known feature of unexplained HBM [28]. Gen-
eralisability of our ﬁndings is limited to Caucasian females, given the
small number of men in this study. Genotype data came from a range of
platforms which introduces heterogeneity and thus could have biased
the discovery results. Our use of stringent ‘information score’ thresholds
and concordance ﬁlters may also have missed true associations. Lastly,
whilst we included both osteocyte and osteoblast expression data, os-
teoclast and chondrocyte expression data were lacking.
5. Conclusions
Common variation in established BMD genes is over-represented in
unexplained HBM, suggesting HBM is, at least in part, polygenic in
origin with contribution from the same genes that determine BMD in
the general population. Functional annotation suggested that genes
particularly contributing to the HBM phenotype are involved in en-
dochondral ossiﬁcation and osteoblast diﬀerentiation and activity. Two
novel BMD-associated loci have been identiﬁed with candidate genes
NRP3 and SPON1, associated with lumbar spine and hip BMD respec-
tively. These ﬁndings are supported by NRP3 and SPON1 bone ex-
pression data; further, both Npr3 and Spon1 have reported mouse
models with altered skeletal phenotypes providing biological validation
that these genes play a functional role in bone. Whilst small, our GWAS
results are certainly hypothesis-generating and highlight potentially
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new anabolic bone regulatory pathways which warrant further study.
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